METHOD OF DETERMINING THROMBIN COMPLEMENTARITY SYSTEM ACTIVATION PATHWAY Russian patent published in 2020 - IPC G01N33/50 

FIELD: immunology.

SUBSTANCE: invention refers to clinical immunology and haemostasiology. Disclosed is a method for determining a thrombin pathway of complement system activation (TPCSA) by human group A erythrocysis lysis, involving using citrated human blood plasma as a source of circulating thrombin, its natural substrate - component C5 and proteins of membrane-attack complex C6, C7, C8 and C9, proteolysis of component C5 of complement thrombin leads to formation of membrane-attack complex and lysis of added erythrocyte 1 % suspension, the TPCSA activity in the sample is determined by turbidimetry after 10-minute incubation at 37 °C according to the calibration curve, where 100 % lysis is complete lysis of human erythrocytes with water addition, and control of erythrocytes on spontaneous lysis - 0 % lysis, in lysis to 30 % human erythrocytes is considered normal activity of thrombin path complement system, from 30 to 60 % - increased activity and more than 60 % of lysis - high activity of human complement's thrombin pathway.

EFFECT: invention provides a novel approach for determining activity of a thrombin pathway of complement system activation, simplifies testing and eliminates multiple contact of the operator with the biomaterial.

1 cl, 3 dwg, 7 tbl, 9 ex